

IN THE CLAIMS:

Claims 1-5 (canceled)

Claim 6 (Currently amended). A method of inhibiting repair of double-stranded breaks in DNA in a cell which comprises introducing into the cell DNA [containing] expressing early region 4 (E4) open reading frame 6 (ORF6) and E1B region of genomic adenoviral DNA, and in which no other early or late gene products are expressed, wherein introduction of the DNA results in inhibition of repair of double-stranded breaks in DNA in said cell.

Claims 7-11 (withdrawn)

Claim 12 (Currently amended). A method for chemotherapeutic or radiation treatment of cancer in a subject while inhibiting repair of double-stranded breaks in DNA in cancer cells in said subject which comprises: a) introducing into said cancer cells DNA [containing] comprising early region 4 (E4) open reading frame 6 (ORF6) and E1B region of genomic adenoviral DNA, in a quantity sufficient to inhibit repair of double-stranded breaks in DNA in said cancer cells and b) administering a chemotherapeutic agent or radiation to the subject.

13 (Currently amended). The method of claim 12, wherein the DNA [containing] comprising early region 4 (E4) open reading frame 6 (ORF6) and E1B region of genomic adenoviral DNA is introduced into the cancer cells before the chemotherapeutic agent or radiation is administered to the subject.

14 (Currently amended). The method of claim 12, wherein the DNA [containing] comprising early region 4 (E4) open reading frame 6 (ORF6) and E1B region of genomic adenoviral DNA is introduced into the cancer cells after the chemotherapeutic agent or radiation is administered to

09/095,565

the subject.

15 (Currently amended). The method of claim 12, wherein the DNA [containing] comprising early region 4 (E4) open reading frame 6 (ORF6) and E1B region of genomic adenoviral DNA is introduced into the cancer cells concurrently with administering the chemotherapeutic agent or radiation is administered to the subject.

16. (Original) The method of claim 12, wherein the chemotherapeutic agent is cisplatin or doxorubicin.

Claims 17-18 (withdrawn).